Acerus Pharma
2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada
Tel: 416-679-0771
Website: http://www.aceruspharma.com/
154 articles about Acerus Pharma
-
Acerus Update - July 11, 2023
7/11/2023
Acerus Pharmaceuticals Corporation announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act and its previously announced sale and investment solicitation process, the Company completed the previously announced transactions with First Generation Capital Inc. as successful bidder under the SISP.
-
Acerus Announces New Loan Agreement With First Generation Capital
12/22/2022
Acerus Pharmaceuticals Corporation have entered into a US$2 million secured loan agreement (the “ Loan Agreement ”) with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus.
-
Acerus Reports Third Quarter 2022 Financial Results
11/15/2022
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and nine-month period ended September 30, 2022.
-
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders
10/3/2022
Acerus Pharmaceuticals Corporation today announced that it has amended the promissory note (the “ Note ”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders.
-
Acerus Announces Initiation of Strategic Review
9/21/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction.
-
Acerus Announces Resignation of CFO Effective November 20, 2022
8/23/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that Robert Motz has informed the Company of his decision to resign as Chief Financial Officer effective November 20, 2022.
-
Acerus Reports Second Quarter 2022 Financial Results
8/9/2022
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and six-month period ended June 30, 2022.
-
Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders
8/5/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus 1 , to increase its existing secured loan facility (the “ Loan Facility ”) from US$37.945 million to US$47.945 million.
-
Acerus to Report Q2-2022 Financial Results and Host Investor Call
8/3/2022
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its second quarter 2022 financial and operating results on Tuesday, August 9, 2022 before the market opens.
-
Acerus Announces Voting Results for the 2022 Annual Meeting
6/27/2022
Acerus Pharmaceuticals Corporation announced the voting results from its annual meeting of shareholders held on June 27, 2022.
-
Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders
6/7/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“ Serenity ”) securityholders.
-
Acerus Reports First Quarter 2022 Financial Results
5/10/2022
Acerus Pharmaceuticals Corporation reported its financial results for the three-month period ended March 31, 2022.
-
Acerus To Report Q1-2022 Financial Results And Host Investor Call
5/5/2022
Acerus Pharmaceuticals Corporation will announce its first quarter 2022 financial and operating results on Tuesday, May 10, 2022 before the market opens.
-
Acerus Announces Completion of Share Consolidation - Apr 26, 2022
4/26/2022
Acerus Pharmaceuticals Corporation announced that further to its news release from April 19, 2022, the Company’s application to consolidate its common shares on the basis of one post-consolidation Share for every two hundred pre-consolidation Shares has been accepted by the Toronto Stock Exchange.
-
Acerus Announces Share Consolidation - Apr 19, 2022
4/19/2022
Acerus Pharmaceuticals Corporation announced that the Company intends to undertake a consolidation of its outstanding common shares on the basis of one post-consolidation share for every two hundred pre-consolidation shares.
-
Acerus Announces Amendments to Loan Facility
3/31/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc.
-
Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Acerus Pharmaceuticals Corporation reported its financial results for the three and twelve-month period ended December 31, 2021.
-
Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
3/10/2022
Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) will announce its fourth quarter and full year 2021 financial and operating results on Tuesday, March 15, 2022 before the market opens.
-
Acerus Announces Amendment to Loan Facilities
2/18/2022
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus 1 , to increase its secured loan facility (the “ Loan Facility ”) from US$25 million to US$30.845 million.
-
Acerus Announces Amendments to Loan Facilities
12/13/2021
Acerus Pharmaceuticals Corporation today announced that it has entered into an amending agreement with First Generation Capital Inc. to increase the existing subordinated secured loan facility from US$15 million to US$25 million.